A Phase II Trial of Revlimid, as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)

Trial Profile

A Phase II Trial of Revlimid, as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 22 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top